Hypomethylating therapy with or without eltrombopag in elderly patients with acute myeloid leukemia: results from the randomized, placebo-controlled phase 2 DELTA Trial

Primary endpoint treatment-change-free survival (TCFS), defined as time from randomization to death or initiation of a new disease-modifying treatment in the phase 2 DELTA trial. AML, acute myeloid leukemia; EPAG, eltrombopag; HMA, hypomethylating agents; IC, intensive chemotherapy.

Saved in:
Bibliographic Details
Main Authors: Sockel, Katja (Author) , Röllig, Christoph (Author) , Mütherig, Anke (Author) , Crysandt, Martina (Author) , Zukunft, Sven (Author) , Herbst, Regina (Author) , Noppeney, Richard (Author) , Schäfer-Eckardt, Kerstin (Author) , Kaufmann, Martin (Author) , Oelschlaegel, Uta (Author) , Fiebig, Frank (Author) , Giagounides, Aristoteles (Author) , Götze, Katharina (Author) , Scholl, Sebastian (Author) , Lück, Andreas (Author) , Rieger, Kathrin (Author) , Geer, Thomas (Author) , Kiewe, Philipp (Author) , Müller-Tidow, Carsten (Author) , Serve, Hubert (Author) , Baldus, Claudia D. (Author) , Kaiser, Ulrich (Author) , Mahlmann, Stefan (Author) , Schmidt, Burkhard (Author) , Parmentier, Stefani (Author) , Illmer, Thomas (Author) , Seggewiss-Bernhardt, Ruth (Author) , Kiani, Alexander (Author) , Linde, Hartmut (Author) , Dürk, Heinz (Author) , Kramer, Michael (Author) , Kunadt, Desiree (Author) , Schmidt-Brücken, Katharina (Author) , Balaian, Ekaterina (Author) , Trautmann-Grill, Karolin (Author) , Ruhnke, Leo (Author) , Middeke, Jan Moritz (Author) , von Bonin, Malte (Author) , Ehninger, Gerhard (Author) , Thiede, Christian (Author) , Bornhäuser, Martin (Author) , Schetelig, Johannes (Author) , Platzbecker, Uwe (Author)
Format: Article (Journal)
Language:English
Published: [02 October 2025]
In: American journal of hematology
Year: 2025, Volume: 100, Issue: 12, Pages: 2436-2441
ISSN:1096-8652
DOI:10.1002/ajh.70091
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1002/ajh.70091
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.70091
Get full text
Author Notes:Katja Sockel, Christoph Röllig, Anke Mütherig, Martina Crysandt, Sven Zukunft, Regina Herbst, Richard Noppeney, Kerstin Schäfer-Eckardt, Martin Kaufmann, Uta Oelschlaegel, Frank Fiebig, Aristoteles Giagounides, Katharina Götze, Sebastian Scholl, Andreas Lück, Kathrin Rieger, Thomas Geer, Philipp Kiewe, Carsten Müller-Tidow, Hubert Serve, Claudia D. Baldus, Ulrich Kaiser, Stefan Mahlmann, Burkhard Schmidt, Stefani Parmentier, Thomas Illmer, Ruth Seggewiss-Bernhardt, Alexander Kiani, Hartmut Linde, Heinz Dürk, Michael Kramer, Desiree Kunadt, Katharina Schmidt-Brücken, Ekaterina Balaian, Karolin Trautmann-Grill, Leo Ruhnke, Jan Moritz Middeke, Malte von Bonin, Gerhard Ehninger, Christian Thiede, Martin Bornhäuser, Johannes Schetelig, Uwe Platzbecker
Description
Summary:Primary endpoint treatment-change-free survival (TCFS), defined as time from randomization to death or initiation of a new disease-modifying treatment in the phase 2 DELTA trial. AML, acute myeloid leukemia; EPAG, eltrombopag; HMA, hypomethylating agents; IC, intensive chemotherapy.
Item Description:Gesehen am 09.04.2026
Physical Description:Online Resource
ISSN:1096-8652
DOI:10.1002/ajh.70091